Go to content
UR Home

[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line

URN to cite this document:
DOI to cite this document:
Bernhardt, Günther ; Gust, Ronald ; Reile, Herta ; vom Orde, Hans Dieter ; Müller, Richard ; Keller, Christoph ; Spruß, Thilo ; Schönenberger, Helmut ; Burgemeister, Thomas ; Mannschreck, Albrecht ; Range, Klaus Jürgen ; Klement, Ulrich
Date of publication of this fulltext: 05 Aug 2009 13:48


The stereoisomeric [1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes were thoroughly tested on the cisplatin-resistant human NIH:OVCAR-3 ovarian cancer cell line. The racemate and its enantiomers produced cytocidal effects at a concentration of 2.5 microM (incubation time 256 h). The meso form, however, was merely cytostatically active. Differences between the enantiomers ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons